Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jiangsu Recbio Technology Co., Ltd. Class H ( (HK:2179) ) has shared an update.
Jiangsu Recbio Technology Co., Ltd. has announced the current composition of its board of directors, comprising executive, non-executive and independent non-executive directors, with Dr. Liu Yong serving as chairman. The company has also detailed the membership and leadership of its three key board committees—Audit Committee, Remuneration and Appraisal Committee, and Nomination Committee—clarifying the oversight structure and governance responsibilities, which underscores its commitment to corporate governance and transparency for shareholders and other stakeholders.
The most recent analyst rating on (HK:2179) stock is a Sell with a HK$5.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.
More about Jiangsu Recbio Technology Co., Ltd. Class H
Jiangsu Recbio Technology Co., Ltd. is a biotechnology company incorporated as a joint stock company in Jiangsu Province, China, and listed in Hong Kong under stock code 2179. It operates in the biopharmaceutical sector, focusing on the research, development and commercialization of innovative vaccines and related technologies for domestic and international healthcare markets.
Average Trading Volume: 42,323
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.63B
For a thorough assessment of 2179 stock, go to TipRanks’ Stock Analysis page.